Taking Charge—biotechs already approaching Novartis to partner on 'game changing' CAR-T platform

With the first generation of CAR-T therapies having shaken up the cancer space, all eyes are on what comes next. So it shouldn’t be a surprise that biotechs have already been in touch with Novartis to see whether they can jump onto the Swiss pharma’s T-Charge platform.